30 January 2026 - The EMA’s CHMP has adopted a positive opinion recommending the conditional marketing authorisation of Rezurock (belumosudil) in the EU for the treatment of adults and in children aged 12 years and older with a body weight of at least 40 kg, with chronic graft versus host disease. 

The medicine is to be used when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.

This positive recommendation comes after Sanofi requested a re-examination of the prior negative opinion adopted by the CHMP in October 2025.

Read Sanofi press release